NCT02065765 2025-01-09International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric CancerEli Lilly and CompanyApproved for marketing
NCT02307812 2025-01-09Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in FranceEli Lilly and CompanyApproved for marketing